Results 91 to 100 of about 7,608 (177)

Effect of Botulinum Toxin-A Injection on Intraocular Pressure and Proptosis in Thyroid Associated Orbitopathy [PDF]

open access: yes, 2009
The aim of this study was to evaluate the effects of extraocular muscle injection of botulinum toxin-A (BTX-A) on intraocular pressure (IOP) and proptosis in patients with ocular motility disturbances in thyroid associated orbitopathy (TAO).
Davor Galetović   +6 more
core   +1 more source

Morphometric analysis of eyelid fissure in patients with eyelid retraction in acute stage of dysthyroid orbitopathy after treatment with botulinum toxin type A [PDF]

open access: yes, 2008
OBJETIVO: Apresentar dados morfométricos da fenda palpebral, antes e após a aplicação da toxina botulínica tipo A em pacientes com retração palpebral na fase aguda da orbitopatia distireoidiana.
COSTA, Patrícia Grativol   +3 more
core   +2 more sources

TSH-receptor antibodies may prevent bone loss in pre- and postmenopausal women with Graves' disease and Graves' orbitopathy

open access: yesArchives of Endocrinology and Metabolism
Objective Thyrotoxicosis is established risk factor for osteoporosis due to increased bone turnover. Glucocorticoids often administered for Graves' orbitopathy (GO) have additional negative effect on bone mineral density (BMD). Our aim was to examine the
Mira Siderova   +2 more
doaj   +1 more source

Evaluation of Quality of Life in the Brazilian Graves' Disease Population: Focus on Mild and Moderate Graves' Orbitopathy Patients

open access: yesFrontiers in Endocrinology, 2019
Background: Quality of life (QoL) studies in patients with mild to moderate Graves' orbitopathy (GO) are scarce.Methods: The original GO-QoL questionnaire was translated to Portuguese and administered to 323 patients with Graves' disease.
Danilo Villagelin   +8 more
doaj   +1 more source

Graves’ orbitopathy after allogeneic bone marrow transplantation in a patient with Fanconi anemia – side effect of alemtuzumab therapy?

open access: yesClinical Case Reports, 2018
Key Clinical Message A few cases of thyroid eye disease following alemtuzumab therapy have been described in patients with multiple sclerosis. Our patient is the first case of Graves’ orbitopathy after alemtuzumab conditioning for hematopoietic stem cell
Luminita Nicoleta Cima   +5 more
doaj   +1 more source

Targeted immunotherapies for Graves’ thyroidal & orbital diseases

open access: yesFrontiers in Immunology
BackgroundGraves’ hyperthyroidism and its associated Graves’ orbitopathy are common autoimmune disorders associated with significant adverse health impact.
Alan Chun Hong Lee, George J. Kahaly
doaj   +1 more source

Endoscopic transnasal orbital decompression for thyrotoxic orbitopathy [PDF]

open access: yes, 2002
Objective. To evaluate the efficacy of endoscopic transnasal orbital decompression alone for thyrotoxic orbitopathy. Design. Retrospective review of consecutive procedures. Setting. Tertiary referral otorhinolaryngology centre. Patients.
Chan, E   +4 more
core  

Steroid Treatment Focused Management of Graves’ Ophthalmopathy

open access: yesActa Medica Bulgarica
Graves' disease (GD) is an autoimmune disease that affects the thyroid and the eyes. Graves' ophthalmopathy (GO), an autoimmune disease, usually appears 18 months after GD diagnosis.
Condeng Y. H.   +5 more
doaj   +1 more source

Association between lipid profiles and Graves orbitopathy: A systematic review and meta analysis

open access: yesEndocrine and Metabolic Science
Introduction: Graves orbitopathy (GO) is an autoimmune disorder affecting the tissues around the eyes, seen in 25–50 % of individuals with Graves disease (GD).
Nanny Natalia Mulyani Soetedjo   +5 more
doaj   +1 more source

Biomarkers of ocular surface disease using impression cytology [PDF]

open access: yes, 2017
Aronni S   +10 more
core   +2 more sources

Home - About - Disclaimer - Privacy